A Exploratory Phase II Clinical Trial, Double-blind, Randomized Placebo-controlled to Evaluate the Efficacy of RUTI Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers
Latest Information Update: 31 Jan 2023
At a glance
- Drugs Tuberculosis-vaccine-Archivel-Farma (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors RUTI Immunotherapeutics
- 25 Jan 2023 Status changed from recruiting to completed.
- 31 May 2021 New trial record